Pharmacoscintigraphic Study to Evaluate Two Sildenafil Products
A Pharmacoscintigraphic Clinical Study to Evaluate a Biphasic Release Sildenafil Formulation (With Immediate and Sustained Release Components) Compared to a Marketed Sildenafil Product in Fed and Fasted States
Sponsor: BDD Pharma Ltd
Listed as NCT03510338, this PHASE1 trial focuses on Erectile Dysfunction and remains completed. Sponsored by BDD Pharma Ltd, it has been updated 6 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Aug 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Not Yet Recruiting → Completed
-
Jun 2018 — Aug 2018 [monthly]
Not Yet Recruiting PHASE1
▶ Show 1 earlier version
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- BDD Pharma Ltd
- N4 Pharma UK Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .